Skip to content

Challenges and opportunities for innovation in Endometriosis

Challenges and opportunities for innovation in Endometriosis

Challenges and opportunities for innovation in Endometriosis with Dr. Liliane Brunner Halbach

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of Scailyte’s Endometriosis Awareness Series, where Cinzia Donato interviews Dr. Liliane Brunner Halbach on the “Challenges and opportunities for innovation in endometriosis”.

Dr. Liliane Halbach is an experienced healthcare expert with 20+ years of global experience in drug research and development, global product strategy, and business development. With a MSc in Pharmacy and a PhD in Pharmacology from the University of Basel, Switzerland, she has worked in different roles in headquarters and affiliates of Novartis, Roche, and AstraZeneca in Switzerland, Spain, the US, and Singapore.

In addition to her work in the pharmaceutical industry, Dr. Liliane Halbach has been involved with SPARK, a mentoring program that helps researchers bring ideas to a proof-of-concept stage, since 2012, and now leads SPARK Zurich. Two years ago, she joined the Artemis group, a team of experts from VC and Pharma with the goal to bring more innovation to women’s health. After two years of talking to stakeholders and analyzing the gaps, the group founded Artemis Women’s Health Foundation in February 2023 to connect the ecosystem of investors with innovators and find solutions to the issues observed in women’s health.

In this episode, Dr. Liliane Halbach shares her insights on the challenges and opportunities for innovation in endometriosis. Don’t miss out on this exciting conversation and join us to learn more about the latest developments in the field of endometriosis research and innovation.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News